Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TISLELIZUMAB-JSGR for Diffuse large b-cell lymphoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 8 adverse event reports in the FDA FAERS database where TISLELIZUMAB-JSGR was used for Diffuse large b-cell lymphoma.

Most Reported Side Effects for TISLELIZUMAB-JSGR

Side Effect Reports % Deaths Hosp.
Disease progression 15 30.0% 2 0
Off label use 9 18.0% 2 1
Anaemia 8 16.0% 1 1
Pneumonia 8 16.0% 2 7
Lymphadenopathy 7 14.0% 0 0
Thrombocytopenia 7 14.0% 0 0
Infusion related reaction 6 12.0% 0 6
Pyrexia 6 12.0% 0 5
Death 5 10.0% 5 0

Other Indications for TISLELIZUMAB-JSGR

Oesophageal adenocarcinoma (13) Oesophageal squamous cell carcinoma (11) Product used for unknown indication (10) Richter's syndrome (9) Chronic lymphocytic leukaemia (8) Gastrooesophageal reflux disease (6) Prophylaxis (6)

Other Drugs Used for Diffuse large b-cell lymphoma

RITUXIMAB (22,275) CYCLOPHOSPHAMIDE (16,598) DOXORUBICIN (15,213) VINCRISTINE (14,922) PREDNISONE (11,266) LENALIDOMIDE (7,858) ETOPOSIDE (4,698) PREDNISOLONE (4,086) CYTARABINE (3,857) DEXAMETHASONE (3,696)

Related Pages

TISLELIZUMAB-JSGR Full Profile All Diffuse large b-cell lymphoma Drugs TISLELIZUMAB-JSGR Demographics TISLELIZUMAB-JSGR Timeline